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Metabolic activities of orexin A (OXA) in mature adipocytes are mediated via PI3K/PKB and PPARc.
However, the effects of OXA on preadipocytes are largely unknown. We report here that OXA stim-
ulates the proliferation and viability of 3T3-L1 preadipocytes and protects them from apoptosis via
ERK1/2, but not through PKB. OXA reduces proapoptotic activity of caspase-3 via ERK1/2. Inhibition
of ERK1/2 prevents the differentiation of preadipocytes into adipocytes. Unlike insulin, neither
short-term nor prolonged exposure of 3T3-L1 preadipocytes to OXA induces preadipocyte differen-
tiation to adipocytes, despite increased ERK1/2 phosphorylation. Unlike insulin, OXA fails to activate
PKB, which explains its inability to induce the differentiation of preadipocytes.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction Recently, we and others showed that the neuropeptide orexin AThe differentiation of ﬁbroblastic precursor cells (preadipo-
cytes) into adipocytes is controlled by the orchestration of multiple
transcription factors [1]. PPARc and C/EBP are indispensable tran-
scription factors for adipocytes differentiation. Exposure of 3T3-L1
ﬁbroblasts to stimuli of cAMP production (IBMX), together with
PI3K/PKB activators, and dexamethasone (DEXA) leads to differen-
tiation of these cells into mature adipocytes [2–4].chemical Societies. Published by E
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Strowski).(OXA) regulates metabolic and endocrine functions in human and
rodent mature adipocytes [5,6]. OXA also increased lipid accumu-
lation, adiponectin secretion, glucose uptake and inhibited lipoly-
sis in 3T3-L1 adipocytes through a PPARc-dependent pathway
[5]. Since OXA also stimulated 3T3-L1 ﬁbroblasts proliferation
[7], we assumed that OXA also inﬂuences the differentiation of pre-
adipocytes into mature adipocytes. To test this hypothesis, we
studied whether OXA can induce the adipocytes differentiation
and characterized the mechanisms underlying the proliferative
activity of OXA in 3T3-L1 preadipocytes.
2. Materials and methods
2.1. Reagents
Unless otherwise stated, all reagents were from Sigma–Aldrich
(Deisenhofen, Germany). LY294002, U0126 (both used at 10 lM)
and MTT were from Calbiochem (San Diego, CA, USA). DMEM and
supplements for cell culture were from GIBCO Invitrogen
(Karlsruhe, Germany). Speciﬁcations of all antibodies are given in
Supplementary Table 1.lsevier B.V. All rights reserved.
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3T3-L1 and NIH/3T3 ﬁbroblasts (ATCC, LGC Standards, Wesel,
Germany) were maintained in a standard growth medium (SGM:
DMEM, 10% FCS, 100 kU/l penicillin, 100 mg/l streptomycin) at
37 C in a humidiﬁed atmosphere (5% CO2, 95% O2).
2.3. Isolation and differentiation of rat primary preadipocytes
Rat preadipocytes were isolated as previously described [8]. Dif-
ferentiation was induced by treatment with DMEM/F12 medium
supplemented with 2 nM T3, 167 nM insulin and 30 nM dexameth-
asone with or without 100 nM OXA for 5 days.
2.4. 3T3-L1 ﬁbroblasts differentiation
Two days post-conﬂuent 3T3-L1 preadipocytes were differenti-
ated in SGM supplemented with 1 lM DEXA and 500 lM IBMX
with or without 100 nM OXA, or 1 lM insulin. After 2 days, med-
ium was replaced by DMEM (10% FCS) containing either 100 nM
OXA or 1 lM insulin, and cells were incubated for an additional
2 and 4 days, respectively. In a parallel study evaluating ERK1/2
regulation, cells were incubated in standard differentiation
medium (SDM: DMEM, 10% FCS, 1 lM DEXA, 500 lM IBMX) in
the presence or absence of 10 lMU0126 for 2 days. Two additional
groups were incubated in SDM supplemented with insulin (1 lM)
or OXA (100 nM). Then cells were harvested for the quantiﬁcation
of Pparc and C/ebpa mRNA levels or cultured in SGM for an addi-
tional 2 and 4 days, respectively. Cellular triacylglycerol content
was then measured.
2.5. Proliferation
3T3-L1, NIH/3T3 or isolated rat primary preadipocytes were
seeded (2  103 cells/well) in 96-well plates and cultured for
24 h. To synchronize cell cycle, cells were serum-deprived for
24 h and then treated with test agents for a further 24 h. BrdU solu-
tion (10 lM) was then added and cells were incubated for 2.5 h.
The BrdU incorporation into the DNA was measured by Cell Prolif-
eration ELISA BrdU colorimetric kit (Roche Diagnostics, Penzberg,
Germany).
2.6. Cell viability
3T3-L1 preadipocytes were seeded (2  103 cells/well) in 96-
well plates and cultured for 24 h. Following incubation in a serum-
free DMEM supplemented with test agents for 48 h, MTT solution
(0.5 mg/ml) was added. After an additional 3 h, the culture medium
was removed and the formed formazan crystals were dissolved in
100 ll DMSO.Optical densitywasmeasured by a plate reader (Spec-
traMax Plus384 microplate reader, Molecular Devices, Ismaning,
Germany) at 570 nm and 650 nm (reference wave length).
2.7. Preparation and administration of palmitic acid
Palmitic acid solution was prepared and administrated as previ-
ously described [9].
2.8. Cell death
3T3-L1 ﬁbroblasts were cultured in six-well plates to 80% con-
ﬂuency and treated with 100 nM OXA with or without 10 lM
U0126 for 48 h in serum-free DMEMwith or without PA. Cell death
was assessed by quantifying the cytoplasmic histone-associated
DNA fragments (mono- and oligonucleosomes), using Cell Death
Detection ELISA kit (Roche Diagnostics, Penzberg Germany).2.9. Caspase-3 activity
Preadipocytes were cultured in a serum-free medium in six-
well plates (1.5  105 cells/well). Caspase-3 activity was assessed
using a Caspase-3 Colorimetric Assay Kit (BioVision Inc.,
Headquarters, Milipitas, CA, USA).
2.10. Western blot
Differentiated (day 8 post-differentiation) or non-differentiated
3T3-L1 cells were cultured in six-well plates and serum-deprived
for 24 h before treatment with test agents. Cell lysates, protein iso-
lation and Western blots were performed essentially, as described
[10]. The signal intensities of phosphorylated ERK1/2 or PKB were
measured using Quantity One 1-D Analysis software (Bio-Rad Lab-
oratories, Munich, Germany) and the results were normalized
against total ERK1/2 or total PKB.
2.11. Oil red O staining
Differentiated 3T3-L1 adipocytes were stained with ORO, as de-
scribed [5]. The absorbance reading of the eluate was performed at
500 nm wave length using SpectraMax Plus384 microplate reader
(Molecular Devices, Ismaning, Germany).
2.12. Intracellular triacylglycerol content
After exposure to test peptides, cells were washed with PBS,
scraped and sonicated in a triacylglycerol assay buffer containing
50 mM Tris–HCl (pH 7.4) and 1 mM EDTA. Triacylglycerol was
determined using a colorimetric triacylglycerol kit (Cypress Diag-
nostics, Langdorp, Belgium) and normalized to protein content.
2.13. Real-time PCR
Total RNA isolation, puriﬁcation and quantitative RT-PCR were
performed as described [8]. Sequences of gene-speciﬁc primers
are given in Supplementary Table 2. Data were normalized to Hprt
mRNA.
2.14. Statistical analysis
If not indicated, then data are mean ± S.E.M. of at least three
independent experiments, performed in triplicates. Statistical anal-
ysis was performed using unpaired Student’s t test; ⁄P < 0.05;
⁄⁄P < 0.01 vs. appropriate control group.3. Results
3.1. OXA enhances 3T3-L1 ﬁbroblasts proliferation and viability
OXA (1–100 nM) increased 3T3-L1 cell proliferation in both,
serum-free (Fig. 1A) and serum-containing medium (Fig. 1B).
Moreover, OXA (100 nM) potentiated insulin-stimulated prolifera-
tion (Fig. 1C) and dose-dependently enhanced cell viability
(Fig. 1D). Notably, OXA dose-dependently stimulated the prolifera-
tion of NIH/3T3 ﬁbroblasts (Supplementary Fig. 2).
3.2. OXA increases 3T3-L1 ﬁbroblasts proliferation and viability via
ERK1/2-dependent mechanism
OXA stimulated ERK1/2 phosphorylation by 4-fold over basal
in non-differentiated 3T3-L1 cells, after 5 and 10 min (Fig. 2A), and
by 2-fold over basal after 10 min in mature 3T3-L1 adipocytes
(Fig. 2B). Pharmacological blockade of ERK1/2 but not PI3K
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Fig. 1. OXA stimulates 3T3-L1 ﬁbroblast proliferation and viability. 3T3-L1 preadipocytes were treated with OXA (1–100 nM) for 24 h in the absence (A) or presence of 10%
FCS (B). (C) 3T3-L1 preadipocytes were exposed for 24 h to either 100 nM OXA or 10 nM insulin (INS), or both. Cell proliferation was assessed by BrdU assay (A–C). (D) 3T3-L1
cells were incubated with 100 nM OXA for 48 h and the cell viability was detected by MTT assay.
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D). OXA failed to stimulate 3T3-L1 proliferation and viability in the
presence of ERK1/2 blocker U0126 but not in the presence of PI3K
blocker LY294002 (Fig. 2E and F). These data suggest that ERK1/2
participates in OXA-induced stimulation of proliferation and
viability.
3.3. OXA protects from serum deprivation and palmitic acid-induced
apoptosis
Serum deprivation-induced apoptotic death of 3T3-L1 ﬁbro-
blasts was prevented by OXA (Fig. 3A). OXA failed to protect ﬁbro-
blasts against apoptosis in the presence of U0126 (Fig. 3B). Serum
starvation-induced apoptosis was associated with caspase-3
activation, consistent with the results of a previous study [11]
and Fig. 3C. OXA inhibited serum deprivation-stimulated
caspase-3 activity (Fig. 3C), but was ineffective in the presence of
U0126 (Fig. 3C). These ﬁndings suggest that OXA protects 3T3-L1
ﬁbroblasts against apoptosis and blocks the activation of the
pro-apoptotic executor protease caspase-3 via ERK1/2.
In obesity and type 2 diabetes increased FFA levels contribute to
apoptosis. We therefore tested whether OXA protects 3T3-L1 ﬁbro-
blasts against palmitic acid (PA)-induced apoptosis. PA-stimulated
apoptosis and activation of caspase-3 in 3T3-L1 ﬁbroblasts were
attenuated by OXA (Fig. 3D and E).
3.4. ERK1/2 stimulates preadipocytes differentiation
Due to inconsistencies in the literature [12], we initially clari-
ﬁed the role of ERK1/2 in regulating the differentiation of preadipo-
cytes. Incubation of 3T3-L1 cells in the SDM containing IBMX/DEXAfor 48 h resulted in and a 10-fold (C/ebpa) a 14-fold (Pparc) in-
crease of mRNA expression of both surrogate markers of adipocyte
differentiation (Fig. 4A and B). In the presence of U0126 the in-
creases of Pparc and C/ebpa mRNA expression were lost (Fig. 4A
and B), indicating that ERK1/2 enhances the early differentiation
process.
3.5. OXA fails to enhance the differentiation of 3T3-L1 ﬁbroblasts into
mature adipocytes
Since OXA increased pERK1/2 in 3T3-L1 preadipocytes, we
tested whether OXA enhances the IBMX/DEXA-induced early dif-
ferentiation. Pparc and C/ebpa mRNA expression levels in 3T3-L1
ﬁbroblasts incubated for 48 h (short-term) in the SDM containing
100 nM OXA were comparable to that measured in cells incubated
in the SDM (contains IBMX/DEXA), only (Fig. 4A and B). In contrast,
inclusion of insulin (1 lM) in the SDM potentiated the increases of
both Pparc and C/ebpamRNA in differentiating 3T3-L1 cells (Fig. 4A
and B).
To conﬁrm the role of ERK1/2 in regulating the early-stage pre-
adipocytes differentiation (ﬁrst 48 h), we studied the consequences
of ERK1/2 blockade on triacylglycerol accumulation (additional
surrogate parameter of adipocytes differentiation) [13]. Four
(Fig. 4C) or six days (Fig. 4D) after the onset of differentiation
strongly increased triacylglycerol contents were detected in pre-
adipocytes incubated in SDM. The blockade of the ERK1/2 pathway
during the ﬁrst 48 h of differentiation attenuated cellular triacyl-
glycerol accumulation after 4 (Fig. 4C) or 6 days (Fig. 4D) of differ-
entiation. In contrast, OXA failed to enhance the triacylglycerol
content in 3T3-L1 preadipocytes (Fig. 4C and D). These results
show that the activation of ERK1/2 pathway increases the
mature 3T3-L1 adipocytes
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Fig. 2. OXA increases 3T3-L1 ﬁbroblast proliferation and viability via ERK1/2 dependent mechanism. 3T3-L1 ﬁbroblasts (A) and differentiated 3T3-L1 adipocytes (B) were
treated with 100 nM OXA. ERK1/2 phosphorylation (pERK1/2) was measured by Western blots. Effect of the ERK1/2 inhibitor U0126 (10 lM) (C) or the PI3K inhibitor LY
294002 (10 lM) (D) on 100 nM OXA-stimulated (5 min) ERK1/2 phosphorylation in 3T3-L1 ﬁbroblasts. The signal intensity of the pERK1/2 (corresponds to 42 and 44 kDa)
was normalized against the total ERK1/2 (lower bands of the representative Western blot). The relative expressions of pERK1/2 vs. total ERK1/2 (±S.E.M.) (x-fold induction) are
shown (upper panel). Lower panel: Representative Western blots of pERK1/2 (upper band) and total ERK1/2 (lower band). Effect of U0126 (10 lM) or LY 294002 (10 lM) on
OXA-stimulated 3T3-L1 ﬁbroblasts proliferation after 24 h (E) or cell viability after 48 h (F).
4160 M. Skrzypski et al. / FEBS Letters 586 (2012) 4157–4164differentiation of 3T3-L1 ﬁbroblasts into adipocytes, whereas
short-term (48 h) treatment with OXA – despite stimulation of
ERK1/2 – fails to enhance the differentiation.
While 48 h treatment with OXA was ineffective, we tested
whether a prolonged (up to 6 days) exposure to OXA enhances tri-
acylglycerol accumulation in preadipocytes (Fig. 4E and F). 3T3-L1
ﬁbroblasts were incubated in a SDM supplemented either with
1 lM insulin (positive control) or 100 nM OXA for 2 days. Thereaf-
ter, cells were switched to a SGM and divided into three different
treatment groups. Cells were either continuously incubated either
with OXA or insulin, or in the SGM for 2 or 4 days. During the ﬁrst
2, 4 and 6 days of incubation with OXA, no further increase of cel-
lular triacylglycerol accumulation was detected, as compared to
3T3-L1 preadipocytes incubated in the SGM without OXA (Fig. 4Eand F). Expectedly, preadipocytes differentiated in the presence
of insulin (positive control) showed an increase of intracellular tri-
acylglycerol content (Fig. 4E and F). These data indicate that nei-
ther short- nor long-term incubation in SDM supplemented with
OXA potentiates the differentiation of 3T3-L1 preadipocytes.
Expectedly, also OXA alone was ineffective at inducing 3T3-L1 cell
differentiation (Supplementary Fig. 1A–D).
Activation of PI3K/PKB signaling is required for insulin-induced
adipocytes differentiation [4,14,15]. In mature adipocytes, OXA can
increase PKB phosphorylation [5], however, this has not yet been
investigated in preadipocytes. We therefore tested the ability of
OXA to induce PKB phosphorylation in 3T3-L1 cells during the dif-
ferentiation procedure (Fig. 4G). Expectedly, insulin stimulated
PKB phosphorylation in preadipocytes during the differentiation
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Fig. 3. OXA protects 3T3-L1 ﬁbroblasts against serum deprivation- or palmitic acid-induced apoptosis. Effect of 100 nM OXA on serum-deprivation stimulated apoptosis in
the presence or absence of the ERK1/2 blocker U0126 (10 lM) (A and B). Reduction of caspase-3 activity by OXA (48 h treatment) in the absence of U0126 (C). Note: U0126
prevents OXA at protecting cells against apoptosis and against attenuation of caspase-3 activity (B and C). Attenuation of 0.2 mM palmitic acid-stimulated apoptosis by OXA
(D). Reduction of palmitic acid-stimulated caspase-3 activity by OXA (E).
M. Skrzypski et al. / FEBS Letters 586 (2012) 4157–4164 4161process, whereas OXA was ineffective. Thus, the failure of OXA to
stimulate preadipocytes differentiation is possibly due to the lack
of PKB activation.
3.6. OXA stimulates the proliferation of isolated rat primary
preadipocytes without inﬂuencing their differentiation
We studied the effects of OXA on the proliferation and differen-
tiation of white preadipocytes in more physiological settings using
isolated rat primary preadipocytes. OXA enhanced the proliferation
of rat primary adipocytes (Fig. 5A), however the differentiation into
mature adipocytes, as judged by the morphology and intracellular
triacylglycerol content, was not inﬂuenced by OXA (Fig. 5B–D).
These ﬁndings conﬁrm our observations in 3T3-L1 and NIH/3T3
cells.
4. Discussion
3T3-L1 ﬁbroblasts proliferation is controlled by ERK1/2 path-
way [16,17], however contradictory results (stimulation vs. inhibi-
tion) were reported (reviewed in [12]). In agreement with studies
performed on endothelial and adrenocortical cells [18,19], wereport that OXA activates ERK1/2 pathway. OXA stimulates 3T3-
L1 ﬁbroblasts proliferation and viability, and protects against
apoptotic cell death via ERK1/2-dependent mechanism. An earlier
study demonstrated that ERK1/2 activation protects 3T3-L1 ﬁbro-
blasts from serum starvation-induced apoptosis [16]. Consistent
with this observation, prolonged (48 h) incubation of 3T3-L1 ﬁbro-
blasts with OXA enhanced cell viability and prevented from serum-
deprivation- and PA-induced apoptotic death. These effects of OXA
were reversed by blocking the ERK1/2 pathway, indicating that
OXA stimulates 3T3-L1 cell proliferation and viability, and protects
against apoptotic cell death via the ERK1/2.
3T3-L1 cell proliferation and viability is also stimulated by PI3K/
PKB activators [16,20]. We recently reported that OXA stimulates
PI3K/PKB phosphorylation in mature adipocytes [5] and gluca-
gon-producing cells [10]. In the current study we show that OXA
fails to activate PI3K/PKB pathway and that PI3K/PKB is dispens-
able for OXA-induced stimulation of 3T3-L1 preadipocytes
proliferation, and viability. These results suggest that OXA regu-
lates PI3K/PKB in a cell-type speciﬁc manner (preadipocytes vs.
adipocytes).
Some studies showed that ERK1/2 activation leads to decreased
PPARc activity, thereby inhibiting preadipocytes differentiation
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showing that an early activation of ERK1/2 is crucial for adipocytesdifferentiation [23,24]. Control experiments addressing these
discrepancies, utilizing U0126, show clearly that ERK1/2
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the stimulation of Pparc and C/ebpa mRNA expression, as well as
triacylglycerol accumulation. In line with our data, blockade of
ERK1/2 reduced insulin-stimulated triacylglycerol accumulation
in 3T3-L1 cells incubated in the SDM [25]. These results suggest
that ERK1/2 stimulates 3T3-L1 adipocytes differentiation.
PPARc is known to stimulate adipocytes differentiation [26].
Since OXA stimulates ERK1/2 and Pparc expression in mature
adipocytes [5,6], we predicted that OXA is able to enhance the
differentiation of preadipocytes. Unexpectedly, and in contrast
to insulin, OXA failed to enhance the differentiation of 3T3-L1
cells, despite stimulation of ERK1/2 phosphorylation. Stimuli of
preadipocytes differentiation such as insulin or IGF-1 are known
to increase ERK1/2 phosphorylation in 3T3-L1 cells [27,28]. How-
ever, it has been suggested that the ability of insulin to enhance
the differentiation of preadipocytes depends upon the activation
of the PI3K/PKB pathway. Earlier studies clearly showed that the
blocking of PI3K/PKB signaling prevents the differentiation of
3T3-L1 preadipocytes into mature adipocytes [29,30]. In support
of this observation, overactivity of PKB triggered the spontaneous
differentiation of 3T3-L1 ﬁbroblasts into mature adipocytes [31].
Our current data reveals that OXA is unable to induce PKB phos-
phorylation in 3T3-L1 preadipocytes during early differentiation.
In contrast, stimulation of PKB phosphorylation by insulin leads
to a full differentiation. Thus, the results of our experiments sug-
gest that ERK1/2 activity is required for the induction of preadipo-
cytes differentiation at an early stage; however PKB plays an
essential role in achieving full differentiation. The lack of induc-
tion of 3T3-L1 preadipocytes differentiation into adipocytes by
OXA is in line with the recently published in vivo study showing
that orexin-deﬁcient mice have changes of adipogenesis in brown
but not in white adipocytes [32]. Of note, genetic mice studies
showed that orexin improves insulin sensitivity [33,34]. In this
context orexin’s antiapoptotic and mitogenic actions on preadipo-
cytes may be of physiological relevance. The higher content of
large, hypertrophic adipocytes rather than small sized adipocytes
is associated with metabolic abnormalities (hyperglycemia,
hyperlipidemia, insulin resistance) [35]. Increased content of
small adipocytes is the improvement of insulin sensitivity[36,37]. Although OXA fails to induce the differentiation of
preadipocytes into adipocytes, through an increase of preadipo-
cytes proliferation and the protection against apoptosis, OXA
may remodel the adipose tissue composition, without affecting
fat tissue content. These alterations may lead to improved insulin
sensitivity [34]. Recently, a few groups reported that increased
adipocytes death is a hallmark of obesity [38,39]. Pro-apoptotic
phenotype of adipocytes is associated with increased secretion
of pro-inﬂammatory cytokines and macrophages inﬁltration, con-
tributing to insulin resistance. In line with these data it has been
shown that the inhibition of adipocytes apoptosis is associated
with reduced macrophages inﬁltration and lower insulin resis-
tance, independent of body weight [38]. Therefore, it appears that
the inhibition of apoptosis of adipocytes (e.g. by OXA) may repre-
sent a novel target in the therapy of obesity-associated metabolic
abnormalities.
Finally, by reporting that OXA stimulates NIH/3T3 cells (Supple-
mentary Fig. 2) as well as rat preadipocytes proliferation, without
affecting their differentiation, we conclude that OXA’s activities on
these cell types are a rather general phenomenon.
In summary, our study demonstrates that OXA regulates 3T3-L1
preadipocytes proliferation and survival, reduces the pro-apoptotic
caspase-3 activity, and also protects against apoptotic death in-
duced by serum-deprivation or PA via the ERK1/2 pathway. 3T3-
L1 ﬁbroblasts differentiation into adipocytes depends upon ERK1/
2. Despite increasing ERK1/2 phosphorylation OXA fails to enhance
the differentiation of preadipocytes into adipocytes. In contrast to
insulin, OXA fails to increase PKB phosphorylation in 3T3-L1 pre-
adipocytes, an event that we previously reported in OXA-treated
fully differentiated 3T3-L1 adipocytes [5]. The lack of stimulation
of PKB possibly explains the inability of OXA in enhancing preadi-
pocytes differentiation. Since the effects of OXA on two different
cell lines which are able to differentiate into adipocytes are
transferable to primary preadipocytes, the ﬁndings of this study
may be of physiological signiﬁcance. Based on our recent and cur-
rent results we conclude that OXA cell-type speciﬁcally regulates
the functions of preadipocytes and mature adipocytes, thereby
potentially contributing to improvement of glucose and lipid
homeostasis as reported by recent in vivo studies.
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